A phase I-II study of elacytarabine (CP-4055) in the treatment of patients with ovarian cancer resistant or refractory to platinum therapy

Cancer Chemotherapy and Pharmacology

Volumn 68, Issue 5, 2011, Pages 1347-1353

  Pignata, S ^a   Amant, F ^b   Scambia, G ^c   Sorio, R ^d   Breda, E ^e   Rasch, W ^f   Hernes, K ^f   Pisano, C ^a   Leunen, K ^b   Lorusso, D ^c   Cannella, L ^a   Vergote, I ^b  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b Katholieke Universiteit   (Belgium)

^c CATHOLIC UNIVERSITY   (Italy)

^d CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^e FATEBENEFRATELLI HOSPITAL   (Italy)

^f Clavis Pharma   (Norway)

Author keywords

Chemotherapy; CP 4055; Elacytarabine; Ovarian cancer; Recurrence

Indexed keywords

CA 125 ANTIGEN; CYTARABINE; ELACYTARABINE; PLATINUM COMPLEX; URACIL ARABINOSIDE;

ADULT; ALOPECIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RECURRENCE; CLINICAL ARTICLE; CLINICAL STUDY; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG HALF LIFE; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEMALE; FEVER; HUMAN; HYPOKALEMIA; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; OVARY CANCER; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RECURRENT CANCER; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANTIMETABOLITES, ANTINEOPLASTIC; CYTARABINE; FEMALE; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS;

EID: 82455212282     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-011-1735-4     Document Type: Article

References (26)

1. AP Heintz F Odicino P Maisonneuve MA Quinn JL Benedet WT Creasman, et al. 2006 Carcinoma of the ovary. FIGO 6th annual report on the results of treatment in gynecological cancer Int J Gynaecol Obstet 95 Suppl 1 S161 S192 17161157 10.1016/S0020-7292(06)60033-7 (Pubitemid 44854933)
2. SC Rubin TC Randall KA Armstrong DS Chi WJ Hoskins 1999 Ten-year follow-up of ovarian cancer patients after second-look laparotomy with negative findings Obstet Gynecol 93 21 24 9916949 10.1016/S0029-7844(98)00334-2 1:STN:280:DyaK1M7htl2rtQ%3D%3D
3. S Pignata L Cannella D Leopardo C Pisano GS Bruni G Facchini 2011 Chemotherapy in epithelial ovarian cancer Cancer Lett 303 73 83 21353386 10.1016/j.canlet.2011.01.026 1:CAS:528:DC%2BC3MXisFKitrs%3D
4. AN Gordon JT Fleagle D Guthrie, et al. 2001 Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan J Clin Oncol 19 3312 3322 11454878 1:CAS:528: DC%2BD3MXlvVamsr8%3D (Pubitemid 32642183)
5. AN Gordon M Tonda S Sun, et al. 2004 Long term survival advantage for women treated with pegylated liposomal doxorubicin versus topotecan in a phase III randomized study of recurrent and refractory epithelial ovarian cancer Gynecol Oncol 95 1 8 15385103 10.1016/j.ygyno.2004.07.011 1:CAS:528: DC%2BD2cXnvVOisrg%3D (Pubitemid 39286270)
6. Meier W, du Bois A, Reuss A, Kuhn W, Olbricht S, Gropp M, Richter B, Lück HJ, Kimmig R, Pfisterer J (2009) Topotecan versus treosulfan, an alkylating agent, in patients with epithelial ovarian cancer and relapse within 12 months following 1st-line platinum/paclitaxel chemotherapy. A prospectively randomized phase III trial by the Arbeitsgemeinschaft Gynaekologische Onkologie ovarian cancer study group (AGO-OVAR). Gynecol Oncol 114:199-205
7. D Pectasides A Psyrri M Pectasides, et al. 2006 Optimal therapy for platinum resistant recurrent ovarian cancer: doxorubicin, gemcitabine or topotecan? Expert Opin Pharmacother 7 975 987 16722809 10.1517/14656566.7.8.975 1:CAS:528:DC%2BD28XltVOgsr8%3D (Pubitemid 43949937)
8. G Ferrandina I Paris M Ludovisi, et al. 2005 Gemcitabine and liposomal doxorubicin in the salvage treatment of ovarian cancer: updated results and long-term survival Gynecol Oncol 98 267 273 15975643 10.1016/j.ygyno.2005.04.018 1:CAS:528:DC%2BD2MXmsVWgtbY%3D (Pubitemid 41024849)
9. PG Rose JH Maxson N Fusco, et al. 2001 Liposomal doxorubicin in ovarian, peritoneal, and tubal carcinoma: a retrospective comparative study of single-agent dosages Gynecol Oncol 82 323 328 11531287 10.1006/gyno.2001.6272 1:CAS:528:DC%2BD3MXmsVGjtbY%3D (Pubitemid 32730611)
10. G Ferrandina M Ludovisi D Lorusso, et al. 2008 Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer J Clin Oncol 26 890 896 18281662 10.1200/JCO.2007.13. 6606 1:CAS:528:DC%2BD1cXjtFelsbY%3D (Pubitemid 351398081)
11. Armstrong D (2002) Relapsed ovarian cancer: challenges and management strategies for a chronic disease. Oncologist 7(Suppl 5):20-28
12. BJ Bolwell PA Cassileth RP Gale 1988 High dose cytarabine: a review Leukaemia 2 253 260 1:STN:280:DyaL1c3jtFOmsQ%3D%3D
13. W Plunkett V Gandhi 1993 Cellular pharmacodynamics of anticancer drugs Semin Oncol 20 50 63 8475410 1:CAS:528:DyaK3sXktVSjurY%3D (Pubitemid 23082218)
14. Rustum YM, Raymakers RA (1992) 1-Beta-arabinofuranosylcytosine in therapy of leukaemia: preclinical and clinical overview. Pharmacol Ther 56:307-321 (Pubitemid 23096374)
15. S Grant 1998 Ara-C: cellular and molecular pharmacology Adv Cancer Res 72 197 233 9338077 10.1016/S0065-230X(08)60703-4 1:CAS:528:DyaK2sXotVyktrw%3D (Pubitemid 27435556)
16. S Gailani A Nussbaum 1976 Correlation of response to 1-beta- D-arabinofuranosyl cytosine and metabolism of drug by tumour J Med 7 93 102 1064685 1:STN:280:DyaE283hs1ejtQ%3D%3D
17. Bajetta E, Verusio C, Bonfante V, Bonadonna G (1986) Cytarabine and cisplatin in advanced malignant melanoma. Cancer Treat Rep 70:1441-1442 (Pubitemid 17005127)
18. Chabner BA (1993) Anticancer drugs. In: DeVita VT, Hellman S, Rosenberg SA (eds) Cancer: principles and practice of oncology, 4th edn. JB Lippincott Co, Philadelphia, pp 365-369
19. H Someya WR Waud WB Parker 2006 Long intracellular retention of 4′-thio-arabinofuranosylcytosine 5′-triphosphate as a critical factor for the antisolid tumour activity of 4′- thioarabinofuranosylcytosine Cancer Chemother Pharmacol 57 772 780 16180016 10.1007/s00280-005-0126-0 1:CAS:528:DC%2BD28XjtlWnsrs%3D
20. Breistøl K, Balzarini J, Sandvold ML, Myhren F, Martinsen M, De Clercq F et al. (1999) Antitumour activity of P-4055 (Elaidic Acid-Cytarabine) compared to cytarabine in metastatic and s.c. human tumour xenograft models. Cancer Res 59:2944-2949 (Pubitemid 29283136)
21. DD Ross SR Chen DP Cuddy 1990 Effects of 1-beta-Darabinofuranosylcytosine on DNA replication intermediates monitored by PH-step alkaline elution Cancer Res 50 2658 2666 2328491 1:CAS:528:DyaK3cXit12nsL8%3D (Pubitemid 20150201)
22. AM Bergman CM Kuiper DA Voorn EM Comijn F Myhren ML Sandvold, et al. 2004 Antiproliferative activity and mechanism of action of fatty acid derivatives of arabinofuranosylcytosine in leukaemia and solid tumour cell lines Biochem Pharmacol 67 503 511 15037202 10.1016/j.bcp.2003.09.028 1:CAS:528: DC%2BD2cXhtVahtL0%3D (Pubitemid 38232890)
23. AM Bergman CM Kuiper F Myhren ML Sandvold HR Hendriks GJ Peters 2004 Antiproliferative activity and mechanism of action of fatty acid derivatives of arabinosylcytosine (ara-C) in leukaemia and solid tumour cell lines Nucleosides Nucleotides Nucleic Acids 23 1523 1526 15571290 10.1081/NCN-200027735 1:CAS:528:DC%2BD2cXptFeitL4%3D (Pubitemid 39625956)
24. Dueland S, Aamdal S, Lind MJ, Thomas H, Sandvold ML, Gaullier JM, Rasch W (2009) Intravenous administration of CP-4055 (ELACYT) in patients with solid tumours. A phase I study. Acta Oncol 48(1):137-145
25. Delaunoit T, Raymond E, Awada A, Savinelli F, Culine S, Rasch W et al. (2006) A three schedule phase I trial of CP-4055, weekly and q2 weeks in patients with advanced or metastatic solid tumours. J Clin Oncol (Suppl):267 (abstract)
26. P Therasse SG Arbuck EA Eisenhauer J Wanders RS Kaplan L Rubinstein, et al. 2000 New guidelines to evaluate the response to treatment in solid tumours J Natl Cancer Inst 92 205 216 10655437 10.1093/jnci/92.3.205 1:STN:280: DC%2BD3c7it1Gitg%3D%3D (Pubitemid 30099779)